CD16‐158‐valine chimeric receptor T cells overcome the resistance of KRAS‐mutated colorectal carcinoma cells to cetuximab
KRAS mutations hinder therapeutic efficacy of epidermal growth factor receptor (EGFR)‐specific monoclonal antibodies cetuximab and panitumumab‐based immunotherapy of EGFR+ cancers. Although cetuximab inhibits KRAS‐mutated cancer cell growth in vitro by natural killer (NK) cell‐mediated antibody‐dependent cellular cytotoxicity (ADCC), KRAS‐mutated colorectal carcinoma (CRC) cells escape NK cell immunosurveillance in vivo. To overcome this limitation, we used cetuximab and panitumumab to redirect Fcγ chimeric receptor (CR) T cells against KRAS‐mutated HCT116 colorectal cancer (CRC) cells. We compared four polymorphic Fcγ‐CR constructs including CD16158F‐CR, CD16158V‐CR, CD32131H‐CR, and CD32131R‐CR transduced into T cells by retroviral vectors. Percentages of transduced T cells expressing CD32131H‐CR (83.5 ± 9.5) and CD32131R‐CR (77.7 ± 13.2) were significantly higher than those expressing with CD16158F‐CR (30.3 ± 10.2) and CD16158V‐CR (51.7 ± 13.7) ( p< 0.003). CD32131R‐CR T cells specifically bound soluble cetuximab and panitumumab. However, only CD16158V‐CR T cells released high levels of interferon gamma (IFNγ = 1,145.5 pg/ml ±16.5 pg/ml, p< 0.001) and tumor necrosis factor alpha (TNFα = 614 pg/ml ± 21 pg/ml, p< 0.001) upon incubation with cetuximab‐opsonized HCT116 cells. Moreover, only CD16158V‐CR T cells combined with cetuximab killed HCT116 cells and A549 KRAS‐mutated cells in vitro. CD16158V‐CR T cells also effectively controlled subcutaneous growth of HCT116 cells in CB17‐SCID mice in vivo. Thus, CD16158V‐CR T cells combined with cetuximab represent useful reagents to develop innovative EGFR+KRAS‐mutated CRC immunotherapies..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:146 |
|---|---|
| Enthalten in: |
International Journal of Cancer - 146(2020), 9, Seite 2531-2538 |
| Beteiligte Personen: |
Arriga, Roberto [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2020 UICC |
|---|
| Umfang: |
8 |
|---|
| doi: |
10.1002/ijc.32618 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY007297424 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY007297424 | ||
| 003 | DE-627 | ||
| 005 | 20230307170151.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230216s2020 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/ijc.32618 |2 doi | |
| 028 | 5 | 2 | |a IJC_IJC32618.xml |
| 035 | |a (DE-627)WLY007297424 | ||
| 035 | |a (WILEY)IJC32618 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.81 |2 bkl | ||
| 100 | 1 | |a Arriga, Roberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CD16‐158‐valine chimeric receptor T cells overcome the resistance of KRAS‐mutated colorectal carcinoma cells to cetuximab |
| 264 | 1 | |c 2020 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2020 UICC | ||
| 520 | |a KRAS mutations hinder therapeutic efficacy of epidermal growth factor receptor (EGFR)‐specific monoclonal antibodies cetuximab and panitumumab‐based immunotherapy of EGFR+ cancers. Although cetuximab inhibits KRAS‐mutated cancer cell growth in vitro by natural killer (NK) cell‐mediated antibody‐dependent cellular cytotoxicity (ADCC), KRAS‐mutated colorectal carcinoma (CRC) cells escape NK cell immunosurveillance in vivo. To overcome this limitation, we used cetuximab and panitumumab to redirect Fcγ chimeric receptor (CR) T cells against KRAS‐mutated HCT116 colorectal cancer (CRC) cells. We compared four polymorphic Fcγ‐CR constructs including CD16158F‐CR, CD16158V‐CR, CD32131H‐CR, and CD32131R‐CR transduced into T cells by retroviral vectors. Percentages of transduced T cells expressing CD32131H‐CR (83.5 ± 9.5) and CD32131R‐CR (77.7 ± 13.2) were significantly higher than those expressing with CD16158F‐CR (30.3 ± 10.2) and CD16158V‐CR (51.7 ± 13.7) ( p< 0.003). CD32131R‐CR T cells specifically bound soluble cetuximab and panitumumab. However, only CD16158V‐CR T cells released high levels of interferon gamma (IFNγ = 1,145.5 pg/ml ±16.5 pg/ml, p< 0.001) and tumor necrosis factor alpha (TNFα = 614 pg/ml ± 21 pg/ml, p< 0.001) upon incubation with cetuximab‐opsonized HCT116 cells. Moreover, only CD16158V‐CR T cells combined with cetuximab killed HCT116 cells and A549 KRAS‐mutated cells in vitro. CD16158V‐CR T cells also effectively controlled subcutaneous growth of HCT116 cells in CB17‐SCID mice in vivo. Thus, CD16158V‐CR T cells combined with cetuximab represent useful reagents to develop innovative EGFR+KRAS‐mutated CRC immunotherapies. | ||
| 700 | 1 | |a Caratelli, Sara |4 aut | |
| 700 | 1 | |a Lanzilli, Giulia |4 aut | |
| 700 | 1 | |a Ottaviani, Alessio |4 aut | |
| 700 | 1 | |a Cenciarelli, Carlo |4 aut | |
| 700 | 1 | |a Sconocchia, Tommaso |4 aut | |
| 700 | 1 | |a Spagnoli, Giulio C. |4 aut | |
| 700 | 1 | |a Iezzi, Giandomenica |4 aut | |
| 700 | 1 | |a Roselli, Mario |4 aut | |
| 700 | 1 | |a Lauro, Davide |4 aut | |
| 700 | 1 | |a Coppola, Andrea |4 aut | |
| 700 | 1 | |a Dotti, Gianpietro |4 aut | |
| 700 | 1 | |a Ferrone, Soldano |4 aut | |
| 700 | 1 | |a Sconocchia, Giuseppe |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International Journal of Cancer |g 146(2020), 9, Seite 2531-2538 |w (DE-627)WLY007287127 |x 10970215 |7 nnns |
| 773 | 1 | 8 | |g volume:146 |g year:2020 |g number:9 |g pages:2531-2538 |g extent:8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.81 |q ASE |
| 951 | |a AR | ||
| 952 | |d 146 |j 2020 |e 9 |h 2531-2538 |g 8 | ||